BPC-157 and the peptide boom: what the human evidence actually shows

BPC-157 is the peptide people inject for tendon pain, gym injuries and gut problems, usually on the advice of a podcast, a forum or a telehealth clinic. In 2026 it moved from the fringes to the news, when an advisory panel to the US Food and Drug Administration voted to let compounding pharmacies make it.

That vote is about legal access. It is not about whether the drug works, and on that question the position has barely moved in thirty years: a large pile of animal studies, and a human evidence base small enough to summarise in a paragraph.

What BPC-157 is

BPC-157, short for body protection compound 157, is a synthetic chain of 15 amino acids based on a fragment of a protein found in human gastric juice. It is sold as an injectable, and sometimes as capsules, for healing tendons, ligaments, muscle and gut lining.

It is not an approved medicine anywhere. A 2025 literature review states that it has not been approved by the FDA and other regulators due to the absence of sufficient and comprehensive clinical studies confirming its health benefits in humans. The same review notes that it was temporarily banned by the World Anti-Doping Agency (WADA) in 2022, and a separate systematic review describes its use as banned in professional sports.

The animal evidence is extensive, and narrow in origin

The case for BPC-157 rests on preclinical work. In rodents it has been reported to speed the healing of cut tendons, damaged ligaments, muscle injuries and gut lesions, with proposed mechanisms involving new blood vessel growth and nitric oxide signalling.

Two cautions apply. The first is the usual one: results in rats frequently fail to carry over to people. The second is specific to this peptide. Even a clinic that prescribes peptides describes the literature as rodent studies primarily from the University of Zagreb laboratory of one research group. A finding repeated many times by the same team is not the same as a finding replicated independently.

The human evidence, in full

A systematic review written for orthopaedic and sports medicine doctors searched the literature from 1993 to mid-2024. After duplicates were removed, 36 studies were included (35 preclinical studies, 1 clinical study).

That one clinical study was a retrospective look back at patients who had received the peptide, which the 2025 literature review describes as a retrospective study on 12 patients with knee pain who had an injection into the joint. There was no control group, no blinding and no randomisation, and knee pain often improves on its own.

Counting more generously, a July 2026 review in Pharmacy Times reached the same conclusion with slightly different arithmetic: only 3 uncontrolled pilot studies with a combined sample size of 30 participants have been reported.

There was an attempt at a proper early-stage trial. A Phase I safety study in healthy volunteers was registered, but according to a published exchange between reviewers and the peptide’s main research group, this study was cancelled, and its current status is unknown. No results were ever published.

So the honest count is this: zero randomised controlled trials, for any condition, by any route.

What the FDA vote does and does not mean

In 2023 the FDA placed BPC-157 on a list of substances that compounding pharmacies should not use because they may present significant safety risks. Pharmacy Times summarises the agency’s concern as potential for enhanced immunogenicity, along with minimal establishment of purity, efficacy, or safety.

On 23 July 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend adding BPC-157 to the list of substances pharmacies may compound. As ABC News reported, the vote is non-binding and still needs sign-off from the FDA.

Three points are worth holding on to.

The panel voted against the agency’s own scientists. During the meeting, FDA staff scientists highlighted a general lack of quality data supporting safety and effectiveness. Written testimony to the committee from the consumer group Public Citizen noted that the agency evaluated 25 non-clinical studies and could not identify clinical trials for the uses under review.

Compounding is not approval. If the FDA accepts the recommendation, a doctor could prescribe BPC-157 and a licensed pharmacy could prepare it. That would improve purity compared with vials bought online. It would say nothing about whether the drug heals a tendon.

Several members who voted yes argued that regulated access is safer than the grey market. That is a harm-reduction argument, and it may be a reasonable one, but it is an argument about supply and not about efficacy.

What is not known

Almost everything a patient would want to know. There is no controlled human data on whether BPC-157 speeds tendon or muscle healing. There is no established human dose. There is no published human pharmacokinetic profile from a completed trial. There is no long-term safety data, which matters for a compound whose proposed mechanism involves promoting blood vessel growth.

Product quality is a separate unknown. Vials sold online “for research use only” are outside any pharmaceutical quality system, so the dose and purity of what people are actually injecting are unverified.

What this means for a desk worker with a sore elbow

The injuries BPC-157 is marketed for (tendinopathy, strains, nagging joint pain) are usually managed with graded exercise under the guidance of a physiotherapist. It is slow and dull, and it is the standard first step for a reason.

Injecting an unapproved peptide with no controlled human evidence, bought from a source with no quality assurance, is a poor trade against that. If the regulatory position changes and proper trials follow, the picture may change with it. At the moment there is nothing to weigh.

This is not individual medical advice. Decisions about any injectable or prescription treatment belong with a clinician, and competitive athletes should note that the substance is prohibited in sport.

Common questions

Does BPC-157 work in humans?

Nobody knows. A systematic review found 35 preclinical studies and one clinical study, and a 2026 review counted only 3 uncontrolled pilot studies with 30 participants in total. There are no randomised controlled trials.

Is BPC-157 legal in 2026?

It is not an approved drug. On 23 July 2026 an FDA advisory committee voted 8-6 to recommend allowing compounding pharmacies to prepare it, but that vote is non-binding and still needs FDA sign-off.

Is BPC-157 safe?

Its safety in humans has not been established. The only registered Phase I safety trial was cancelled without published results, and FDA staff told the advisory committee there was a general lack of quality data supporting safety and effectiveness.

Is BPC-157 banned in sport?

Yes for tested athletes. Published reviews note that the World Anti-Doping Agency banned it in 2022 and that its use is banned in professional sports.

The bottom line

BPC-157 has a persuasive story, a large body of rat studies that comes largely from one laboratory, and a human evidence base of about 30 people with no control groups. The 2026 advisory vote may make it easier to get. It does not make it any better tested. Until someone runs a randomised trial, the accurate description is “unproven”, and the sensible treatment for a sore tendon remains a physiotherapist and patience.